U.S. markets closed
  • S&P Futures

    4,395.25
    +11.25 (+0.26%)
     
  • Dow Futures

    34,237.00
    +108.00 (+0.32%)
     
  • Nasdaq Futures

    15,191.00
    +27.50 (+0.18%)
     
  • Russell 2000 Futures

    2,223.30
    +8.40 (+0.38%)
     
  • Crude Oil

    72.39
    +0.16 (+0.22%)
     
  • Gold

    1,762.70
    -16.10 (-0.91%)
     
  • Silver

    23.03
    +0.17 (+0.73%)
     
  • EUR/USD

    1.1708
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3627
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.8510
    +0.0730 (+0.07%)
     
  • BTC-USD

    43,694.00
    +1,447.79 (+3.43%)
     
  • CMC Crypto 200

    1,096.63
    +56.15 (+5.40%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

If You Had Bought United Therapeutics (NASDAQ:UTHR) Shares A Year Ago You'd Have Earned 86% Returns

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could make more than that. To wit, the United Therapeutics Corporation (NASDAQ:UTHR) share price is 86% higher than it was a year ago, much better than the market return of around 54% (not including dividends) in the same period. So that should have shareholders smiling. And shareholders have also done well over the long term, with an increase of 83% in the last three years.

See our latest analysis for United Therapeutics

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During the last year United Therapeutics grew its earnings per share, moving from a loss to a profit.

When a company has just transitioned to profitability, earnings per share growth is not always the best way to look at the share price action.

Revenue was pretty flat year on year, but maybe a closer look at the data can explain the market optimism.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

United Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

We're pleased to report that United Therapeutics shareholders have received a total shareholder return of 86% over one year. That gain is better than the annual TSR over five years, which is 13%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. Before spending more time on United Therapeutics it might be wise to click here to see if insiders have been buying or selling shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.